MCID: TRP003
MIFTS: 38

Triple-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Triple-Receptor Negative Breast Cancer

MalaCards integrated aliases for Triple-Receptor Negative Breast Cancer:

Name: Triple-Receptor Negative Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060081

Summaries for Triple-Receptor Negative Breast Cancer

MalaCards based summary : Triple-Receptor Negative Breast Cancer is related to breast cancer and scirrhous adenocarcinoma. An important gene associated with Triple-Receptor Negative Breast Cancer is ATF5 (Activating Transcription Factor 5), and among its related pathways/superpathways are ERK Signaling and Pathways in cancer. The drugs Pembrolizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include brain and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Triple-Receptor Negative Breast Cancer

Diseases related to Triple-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 breast cancer 27.9 BRCA1 CDC42 ERBB2 ESR1 NOTCH1 PARP1
2 scirrhous adenocarcinoma 10.5 ERBB2 PGR
3 breast apocrine carcinoma 10.5 ERBB2 PGR
4 vulvar syringoma 10.5 ESR1 PGR
5 vestibular gland benign neoplasm 10.5 ESR1 PGR
6 lung leiomyoma 10.4 ESR1 PGR
7 bartholin's gland adenoma 10.4 ESR1 PGR
8 vulvar benign neoplasm 10.4 ESR1 PGR
9 trigonitis 10.4 ESR1 PGR
10 tuberculous salpingitis 10.4 BRCA1 ERBB2
11 vulvar leiomyoma 10.4 ESR1 PGR
12 comedo carcinoma 10.4 ERBB2 ESR1
13 intracystic papillary adenoma 10.4 ERBB2 PGR
14 glassy cell carcinoma of the cervix 10.4 ERBB2 ESR1 PGR
15 progesterone-receptor negative breast cancer 10.4 ERBB2 PGR
16 predominantly cortical thymoma 10.4 ESR1 PGR
17 breast scirrhous carcinoma 10.4 ERBB2 ESR1 PGR
18 progesterone-receptor positive breast cancer 10.3 ERBB2 ESR1 PGR
19 oncocytic breast carcinoma 10.3 ERBB2 ESR1 PGR
20 apocrine adenocarcinoma 10.3 ERBB2 ESR1 PGR
21 breast adenoid cystic carcinoma 10.3 ERBB2 ESR1 PGR
22 luminal breast carcinoma 10.3 ERBB2 ESR1 PGR
23 breast benign neoplasm 10.3 ERBB2 ESR1 PGR
24 thoracic benign neoplasm 10.3 ERBB2 ESR1 PGR
25 nosophobia 10.3 BRCA1 PGR
26 uterine corpus cancer 10.3 ERBB2 ESR1 PGR
27 inflammatory breast carcinoma 10.3 ERBB2 ESR1 PGR
28 mixed cell type cancer 10.3 ERBB2 ESR1 PGR
29 lipid-rich carcinoma 10.3 ERBB2 ESR1 PGR
30 mammary paget's disease 10.3 ERBB2 ESR1 PGR
31 breast metaplastic carcinoma 10.3 ERBB2 ESR1 PGR
32 tubular adenocarcinoma 10.3 ERBB2 ESR1 PGR
33 cancerophobia 10.3 BRCA1 PGR
34 sweat gland cancer 10.3 ERBB2 ESR1 PGR
35 breast fibroadenoma 10.3 ERBB2 ESR1 PGR
36 female breast cancer 10.3 ERBB2 ESR1 PGR
37 uterine corpus serous adenocarcinoma 10.3 BRCA1 ERBB2
38 lobular neoplasia 10.3 BRCA1 ERBB2 ESR1
39 reproductive organ benign neoplasm 10.3 ESR1 PGR TSC2
40 uterine benign neoplasm 10.3 ESR1 PGR TSC2
41 estrogen-receptor positive breast cancer 10.3 ERBB2 ESR1 PGR
42 endometrial adenocarcinoma 10.3 ERBB2 ESR1 PGR
43 progesterone resistance 10.3 ESR1 PGR
44 angiomyolipoma 10.3 ESR1 PGR TSC2
45 primary peritoneal carcinoma 10.2 BRCA1 ERBB2 PGR
46 synchronous bilateral breast carcinoma 10.2 BRCA1 ESR1 PGR
47 breast disease 10.2 ERBB2 ESR1 PGR
48 glycogen-rich clear cell breast carcinoma 10.2 BRCA1 ESR1 PGR
49 cribriform carcinoma 10.2 ESR1 PGR
50 cell type cancer 10.2 ERBB2 ESR1 PGR

Graphical network of the top 20 diseases related to Triple-Receptor Negative Breast Cancer:



Diseases related to Triple-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Triple-Receptor Negative Breast Cancer

GenomeRNAi Phenotypes related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

25 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.05 USP9X
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.05 CDC42
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.05 NOTCH1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.05 USP9X
5 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.05 NOTCH1 NUMB CDC42 USP9X
6 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.05 NUMB
7 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.05 NOTCH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.05 NOTCH1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.05 NUMB
10 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.05 NUMB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.05 NOTCH1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.05 NOTCH1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.05 USP9X
14 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.05 NUMB
15 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.05 CDC42
16 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.05 CDC42
17 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.05 NUMB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.05 NOTCH1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.05 USP9X
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.05 NOTCH1 NUMB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.05 USP9X
22 Decreased viability in esophageal squamous lineage GR00235-A 9.85 ESR1 USP9X ATF5 NUMB BRCA1 PARP1
23 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 RPS6KB1 STK11 CDC42 DAPK1 ERBB2
24 Synthetic lethal with cisplatin GR00101-A-1 8.8 MCL1 NOTCH1 BRCA1

MGI Mouse Phenotypes related to Triple-Receptor Negative Breast Cancer:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 NUMB RPS6KB1 NOTCH1 PGR STMN1 TSC2
2 cellular MP:0005384 10.3 NUMB RPS6KB1 PARP1 NOTCH1 PGR TSC2
3 embryo MP:0005380 10.29 NUMB RPS6KB1 PARP1 NOTCH1 PGR TSC2
4 homeostasis/metabolism MP:0005376 10.27 PGR NUMB RPS6KB1 PARP1 NOTCH1 STMN1
5 hematopoietic system MP:0005397 10.22 NOTCH1 PGR NUMB RPS6KB1 PARP1 TSC2
6 mortality/aging MP:0010768 10.22 NOTCH1 PGR NUMB RPS6KB1 MCL1 PARP1
7 integument MP:0010771 10.17 PARP1 NOTCH1 PGR TFEC TSC2 STK11
8 endocrine/exocrine gland MP:0005379 10.15 NOTCH1 PGR RPS6KB1 MCL1 STK11 TSC2
9 nervous system MP:0003631 10.03 NUMB PARP1 NOTCH1 STMN1 TSC2 STK11
10 normal MP:0002873 10 NUMB MSLN NOTCH1 PGR STMN1 TFEC
11 muscle MP:0005369 9.97 NOTCH1 PGR RPS6KB1 STMN1 STK11 BRCA1
12 neoplasm MP:0002006 9.97 RPS6KB1 NOTCH1 PGR TSC2 STK11 USP9X
13 renal/urinary system MP:0005367 9.56 PARP1 NOTCH1 TSC2 STK11 DAPK1 IGFBP2
14 reproductive system MP:0005389 9.32 NUMB RPS6KB1 PARP1 PGR TSC2 STK11

Drugs & Therapeutics for Triple-Receptor Negative Breast Cancer

Drugs for Triple-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 3 1374853-91-4
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
4
Gemcitabine Approved Phase 2 95058-81-4 60750
5
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
6
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
7
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
8
Epirubicin Approved Phase 2 56420-45-2 41867
9
Everolimus Approved Phase 2 159351-69-6 6442177
10
Fluorouracil Approved Phase 2 51-21-8 3385
11
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
13
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
14 Albumin-Bound Paclitaxel Phase 2
15 Antimitotic Agents Phase 2
16 Antineoplastic Agents, Phytogenic Phase 2
17 Angiogenesis Inhibitors Phase 2
18 Angiogenesis Modulating Agents Phase 2
19 Alkylating Agents Phase 2
20 Anti-Bacterial Agents Phase 2
21 Antibiotics, Antitubercular Phase 2
22 Antifungal Agents Phase 2
23 Anti-Infective Agents Phase 2
24 Antimetabolites Phase 2
25 Antimetabolites, Antineoplastic Phase 2
26 Antirheumatic Agents Phase 2
27 Immunosuppressive Agents Phase 2
28 Topoisomerase Inhibitors Phase 2
29
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
30 Mitogens Phase 2
31 Protein Kinase Inhibitors Phase 2
32 taxane Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
2 EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients Completed NCT00448305 Phase 2 EndoTAG-1 + paclitaxel;EndoTAG-1;Paclitaxel
3 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed NCT00246571 Phase 2 SU011248;Chemotherapy
4 Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer Active, not recruiting NCT00499603 Phase 2 Paclitaxel;5-Fluorouracil;Epirubicin;Cyclophosphamide;RAD001
5 Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer Terminated NCT00739063 Phase 2 Tarceva
6 A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations Terminated NCT02299635 Phase 2 PF-03084014;PF-03084014;PF-03084014

Search NIH Clinical Center for Triple-Receptor Negative Breast Cancer

Genetic Tests for Triple-Receptor Negative Breast Cancer

Anatomical Context for Triple-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Triple-Receptor Negative Breast Cancer:

38
Brain, Breast

Publications for Triple-Receptor Negative Breast Cancer

Articles related to Triple-Receptor Negative Breast Cancer:

(show all 12)
# Title Authors Year
1
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. ( 29235566 )
2018
2
The unmet need for effective treatment of triple-receptor negative breast cancer. ( 25768894 )
2014
3
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. ( 23810431 )
2013
4
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. ( 21800293 )
2012
5
Triple receptor-negative breast cancer: imaging and clinical characteristics. ( 22826413 )
2012
6
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. ( 22359359 )
2012
7
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. ( 21233401 )
2011
8
Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. ( 27958045 )
2011
9
Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? ( 20580045 )
2010
10
Survival among women with triple receptor-negative breast cancer and brain metastases. ( 19150943 )
2009
11
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. ( 19047281 )
2009
12
Advances in triple receptor-negative breast cancer. ( 18277956 )
2007

Variations for Triple-Receptor Negative Breast Cancer

Expression for Triple-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Triple-Receptor Negative Breast Cancer.

Pathways for Triple-Receptor Negative Breast Cancer

Pathways related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 ATF5 BRCA1 CDC42 ERBB2 ESR1 NOTCH1
2 12.46 CDC42 DAPK1 ERBB2 ESR1 NOTCH1 RPS6KB1
3
Show member pathways
12.33 ERBB2 RPS6KB1 STK11 TSC2
4
Show member pathways
12.32 BRCA1 CDC42 MCL1 NOTCH1 RPS6KB1 STK11
5
Show member pathways
12.31 CDC42 ERBB2 ESR1 RPS6KB1
6
Show member pathways
12.3 BRCA1 ERBB2 ESR1 NOTCH1 PGR RPS6KB1
7 12.24 BRCA1 ERBB2 MCL1 NOTCH1 STMN1
8
Show member pathways
12.22 CDC42 RPS6KB1 STK11 TSC2
9 12.1 CDC42 ERBB2 ESR1 RPS6KB1
10
Show member pathways
12 BRCA1 ESR1 PGR RPS6KB1
11 11.95 CDC42 ERBB2 RPS6KB1 STMN1
12 11.73 DAPK1 RPS6KB1 STK11 TSC2
13 11.71 CDC42 ESR1 RPS6KB1
14 11.51 BRCA1 ERBB2 NOTCH1
15 11.44 BRCA1 ERBB2 TSC2
16 11.21 BRCA1 CDC42 ESR1 STK11 TSC2
17 11.2 ESR1 STK11 TSC2

GO Terms for Triple-Receptor Negative Breast Cancer

Cellular components related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.65 ATF5 BRCA1 ESR1 MCL1 NOTCH1 PARP1
2 cytoplasm GO:0005737 9.5 ATF5 BRCA1 CDC42 DAPK1 ERBB2 ESR1

Biological processes related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.85 CDC42 ERBB2 NUMB STK11 STMN1
2 regulation of transcription by RNA polymerase II GO:0006357 9.8 ATF5 BRCA1 ERBB2 ESR1 NOTCH1
3 apoptotic process GO:0006915 9.63 BRCA1 DAPK1 MCL1 PARP1 RPS6KB1 STK11
4 negative regulation of gene expression GO:0010629 9.62 CDC42 ESR1 NOTCH1 PGR
5 positive regulation of transcription by RNA polymerase II GO:0045944 9.5 ATF5 BRCA1 ESR1 NOTCH1 PARP1 PGR
6 negative regulation of anoikis GO:2000811 9.48 MCL1 NOTCH1
7 regulation of epithelial cell proliferation GO:0050678 9.43 NOTCH1 PGR
8 response to estrogen GO:0043627 9.43 BRCA1 ESR1 IGFBP2
9 anoikis GO:0043276 9.37 STK11 TSC2
10 axonogenesis GO:0007409 8.92 NOTCH1 NUMB STK11 STMN1

Molecular functions related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 CDC42 DAPK1 ERBB2 ESR1 PARP1 PGR
2 protein binding GO:0005515 9.6 ATF5 BRCA1 CDC42 DAPK1 ERBB2 ESR1
3 enzyme binding GO:0019899 9.55 BRCA1 ESR1 NOTCH1 PARP1 PGR
4 tubulin binding GO:0015631 9.13 ATF5 BRCA1 STMN1

Sources for Triple-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....